APA (7th ed.) Citation

Modest, D. P., Martens, U. M., Riera-Knorrenschild, J., Greeve, J., Florschütz, A., Wessendorf, S., . . . Geissler, M. (2019). FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). Journal of clinical oncology, 37(35), 3401-3411. https://doi.org/10.1200/JCO.19.01340

Chicago Style (17th ed.) Citation

Modest, Dominik P., et al. "FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)." Journal of Clinical Oncology 37, no. 35 (2019): 3401-3411. https://doi.org/10.1200/JCO.19.01340.

MLA (9th ed.) Citation

Modest, Dominik P., et al. "FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)." Journal of Clinical Oncology, vol. 37, no. 35, 2019, pp. 3401-3411, https://doi.org/10.1200/JCO.19.01340.